2025
Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood Neoplasia 2025, 100159. DOI: 10.1016/j.bneo.2025.100159.Peer-Reviewed Original ResearchSecond malignanciesMyeloproliferative neoplasmsOlder patientsEssential thrombocythemiaPolycythemia veraPhiladelphia chromosome-negative myeloproliferative neoplasmsDevelopment of second malignanciesRisk of non-melanoma skin cancerEnd Results Medicare-linked databaseNon-melanoma skin cancerMedian Follow-UpMedicare-linked databaseTherapy-related effectsRetrospective cohort analysisRisk of SMHazards regression modelsProportion of daysRuxolitinib exposureMedian ageFollow-upRuxolitinibCohort analysisSkin cancerPatientsMyelofibrosis
2012
New health conditions identified at a regional childhood cancer survivor clinic visit
Hogan M, Ma X, Kadan‐Lottick N. New health conditions identified at a regional childhood cancer survivor clinic visit. Pediatric Blood & Cancer 2012, 60: 682-687. PMID: 23023769, DOI: 10.1002/pbc.24360.Peer-Reviewed Original ResearchConceptsNew health conditionsClinic visitsSurvivorship clinicChildhood cancerHealth conditionsOdds ratioChildren's Oncology Group Long-Term FollowCancer treatment exposuresRegular medical careCancer diagnosisPotential treatment-related effectsLong-term followCancer survivorship clinicTherapy-related effectsTreatment-related effectsRisk-based screeningGroup of survivorsSurvivor clinicChest irradiationPulmonary dysfunctionSubsequent cancerLate complicationsNeurologic impairmentAssociated FactorsMultivariate regression model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply